Kennedy and Trump

...

Gabe WhisnantSonam Sheth

By Gabe Whisnant and Sonam Sheth

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


The Department of Health and Human Services (HHS) will end funding and cancel contracts for a series of mRNA-based vaccines aimed at preventing major respiratory illnesses, department Secretary Robert F. Kennedy Jr. announced Tuesday.

HHS will pull a total of $500 million in funding for the vaccines.

Why It Matters

The 22 projects are led by major pharmaceutical companies, including Pfizer and Moderna, and aim to develop vaccines against the flu, COVID-19 and H5N1. mRNA technology, which underpins these vaccines, is widely credited with helping slow the spread of the coronavirus during the 2020 pandemic.

Read More on Politics

Infectious-disease specialists have also warned that future pandemics will be harder to stop without the help of mRNA.

Kennedy has been a longtime vaccine critic and has spread misinformation about their effectiveness on multiple occasions. His tenure as the head of HHS has seen top vaccine experts, food safety supervisors and other public-health officials either resign or be ousted.

View this post on X

Kennedy and Trump

...

What To Know

Kennedy said on Tuesday that half a billion dollars in vaccine development projects will be halted.

"We reviewed the science, listened to the experts, and acted. BARDA (Biomedical Advanced Research and Development Authority) is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu," Kennedy said in an X post. "We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate."

The announcement comes as the U.S. vaccination rate is on a steady multiyear decline, with the Centers for Disease Control and Prevention (CDC) reporting that coverage for all children entering kindergarten in the 2024-25 school year declined for all reported vaccines.

The measles, mumps, rubella (MMR) vaccine has dropped to 92.5 percent, down from 92.7 percent last year. The overall vaccine exemption rate also climbed to 3.6 percent.

Experts are now warning that the declines in vaccine coverage in the United States has led to notable increases in several diseases, including measles, whooping cough and hand, foot and mouth disease.

What People Are Saying

Democratic strategist David Axelrod said on X: "The madness is accelerating: RFK Jr. pulls $500 million in funding for vaccine development."

Dr. Jake Scott, a board-certified infectious-diseases specialist who teaches at the Stanford University School of Medicine, slammed Kennedy's announcement on X, writing: "That framing is naive and reveals a fundamental misunderstanding of vaccinology. It conflates the unrealistic goal of blocking all infections with the real, achievable goal: reducing serious illness and death. No vaccine for respiratory viruses - COVID, flu, RSV - provides durable sterilizing immunity. That was never the standard and shouldn't be the expectation."

He added: "What mRNA vaccines did deliver: the fastest prototype-to-patient timeline in history and a >90% reduction in the risk of invasive ventilation or death. Ending federal support now sacrifices the very speed and flexibility that saved lives."

Mike Osterholm, University of Minnesota expert on infectious disease and pandemic preparations, told the Associated Press: "I don't think I've seen a more dangerous decision in public health in my 50 years in the business."

What Happens Next

In his statement, Kennedy urged the department to shift from mRNA vaccines and "invest in better solutions" but did not specify alternatives. The vast majority of medical experts also disagree with the health secretary's claims about vaccines and their effectiveness.

Update 8/5/25, 8:34 p.m. ET: This article has been updated with additional information and context.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines